
  
    
      
        Background_NNP
        Mitochondrial_NNP cytopathies_NNS are_VBP a_DT heterogeneous_JJ group_NN of_IN
        disorders_NNS that_WDT can_MD affect_VB almost_RB all_DT organ_NN systems_NNS
        reflecting_VBG ATP_NNP depletion_NN ._. Neuromuscular_NNP disorders_NNS were_VBD the_DT
        first_JJ to_TO be_VB studied_VBN ,_, and_CC direct_JJ evidence_NN of_IN mitochondrial_NN
        DNA_NNP (_( mtDNA_NN )_) abnormalities_NNS was_VBD demonstrated_VBN in_IN 1988_CD [_NN 1_CD 2_CD ]_NN
        ._. However_RB ,_, only_RB 6_CD %_NN of_IN the_DT patients_NNS suspected_VBN of_IN having_VBG
        mitochondrial_NN disorders_NNS have_VBP been_VBN found_VBN to_TO have_VB mtDNA_NN point_NN
        mutations_NNS or_CC deletions_NNS [_NN 3_CD ]_NN ._. Most_JJS pediatric_JJ mitochondrial_NN
        disorders_NNS are_VBP caused_VBN by_IN defects_NNS in_IN nuclear_JJ genes_NNS and_CC with_IN
        an_DT autosomal_NN recessive_JJ inheritance_NN [_NN 4_CD ]_NN ._. This_DT case_NN of_IN
        neonatal_NN mitochondrial_NN dysfunction_NN presenting_VBG with_IN
        hyperammonemia_NN and_CC ventricular_NN tachycardia_NN expands_VBZ the_DT
        clinical_JJ spectrum_NN of_IN these_DT disorders_NNS ._.
      
      
        Case_NN presentation_NN
        We_PRP report_VBP the_DT case_NN of_IN a_DT 1_CD day-old_JJ neonate_NN with_IN unusual_JJ
        presenting_VBG features_NNS of_IN a_DT mitochondrial_NN cytopathy_NN and_CC a_DT
        unique_JJ clinical_JJ course_NN ._. She_PRP was_VBD born_VBN at_IN term_NN after_IN an_DT
        uncomplicated_JJ pregnancy_NN to_TO healthy_JJ ,_, unrelated_JJ parents_NNS of_IN
        Northern_JJ European_JJ descent_NN with_IN a_DT negative_JJ family_NN history_NN ._.
        On_IN her_PRP$ first_JJ day_NN of_IN life_NN ,_, she_PRP was_VBD noted_VBN to_TO be_VB lethargic_JJ ,_,
        and_CC was_VBD feeding_VBG poorly_RB ._. Persistent_NNP hypoglycemia_NN ,_,
        hypothermia_NN and_CC seizures_NNS precipitated_VBD her_PRP$ transfer_NN to_TO the_DT
        neonatal_NN intensive_JJ care_NN unit_NN ._. On_IN physical_JJ exam_NN she_PRP was_VBD
        found_VBN to_TO be_VB a_DT non-dysmorphic_JJ ,_, term_NN female_JJ ._. Birth_NNP weight_NN was_VBD
        3515_CD grams_NNS (_( 80_CD thcentile_NN )_) ,_, length_NN was_VBD 48_CD ._. 6_CD cm_NN (_( 50_CD
        thcentile_NN )_) and_CC head_NN circumference_NN was_VBD 35_CD cm_NN (_( 75_CD thcentile_NN )_) ._.
        Significant_JJ findings_NNS on_IN her_PRP$ physical_JJ exam_NN included_VBD a_DT
        distended_JJ abdomen_NN with_IN hepatomegaly_RB and_CC hypotonia_NN ._. Tests_NNP
        for_IN bacterial_JJ and_CC viral_JJ infections_NNS were_VBD ultimately_RB
        negative_JJ ._. The_DT patient_NN was_VBD noted_VBN to_TO have_VB hypoglycemia_NN (_( 30_CD
        mg_NN /_NN dl_NN )_) with_IN a_DT small_JJ amount_NN of_IN ketones_NNS in_IN the_DT urine_NN ._. She_PRP had_VBD
        an_DT elevated_VBD ammonia_NN level_NN of_IN 357_CD μmol_NN /_NN L_NNP (_( normal_JJ range_NN :_:
        22_CD -_: 48_CD )_) ,_, lactic_JJ acid_NN of_IN 10_CD mmol_NN /_NN l_NN (_( normal_JJ range_NN :_: 0_CD ._. 2_CD -_: 2_LS )_) ,_,
        elevated_VBD transaminases_NNS with_IN an_DT alanine_NN aminotransferase_NN of_IN
        69_CD U_NNP /_NN L_NNP (_( normal_JJ range_NN :_: 10_CD -_: 25_CD )_) ,_, an_DT aspartate_NN aminotransferase_NN
        of_IN 162_CD U_NNP /_NN L_NNP (_( normal_JJ range_NN :_: 15_CD -_: 50_CD )_) ,_, and_CC hypothermia_NN with_IN
        deteriorating_VBG neurological_JJ condition_NN ._. She_PRP was_VBD subsequently_RB
        treated_VBN with_IN intravenous_JJ glucose_NN ._. Sodium_NNP benzoate_NN ,_, sodium_NN
        acetate_NN ,_, and_CC arginine_NN hydrochloride_NN were_VBD administered_VBN
        intravenously_RB to_TO treat_VB her_PRP$ hyperammonemia_NN that_IN eventually_RB
        responded_VBD twenty-four_JJ hours_NNS after_IN initiation_NN of_IN therapy_NN ._. In_IN
        view_NN of_IN her_PRP$ hyperammonemia_NN ,_, she_PRP was_VBD placed_VBN on_IN a_DT
        protein-restricted_JJ diet_NN (_( 2_CD g_SYM /_NN kg_NN /_NN day_NN )_) at_IN 3_CD days_NNS of_IN age_NN ._. Her_PRP$
        neurologic_JJ status_NN improved_VBN steadily_RB after_IN her_PRP$
        hyperammonemia_NN was_VBD controlled_VBN ._. Brain_NNP MRI_NNP was_VBD reportedly_RB
        normal_JJ ._. Electroencephalogram_NNP demonstrated_VBD diffuse_NN
        encephalopathy_NN ._. Her_PRP$ initial_JJ presentation_NN with_IN
        hyperammonemia_NN prompted_VBD a_DT genetics_NNS consult_VB ._. Plasma_NNP amino_JJ
        acid_NN analysis_NN showed_VBD an_DT elevated_VBD alanine_NN of_IN 631_CD μmol_NN /_NN L_NNP
        (_( normal_JJ range_NN :_: 141_CD -_: 343_CD )_) with_IN no_DT other_JJ abnormalities_NNS ._.
        Measurement_NNP of_IN carnitine_NN levels_NNS showed_VBD no_DT evidence_NN of_IN
        carnitine_NN depletion_NN ._. However_RB tandem_JJ mass_NN spectrometry_NN of_IN
        acylcarnitines_NNS revealed_VBD a_DT slightly_RB elevated_VBD
        propionylcarnitine_NN of_IN 1_CD ._. 4_CD μM_NN (_( normal_JJ range_NN :_: 0_CD -_: 0_CD ._. 4_LS μM_NN )_) that_WDT
        was_VBD not_RB to_TO the_DT extent_NN seen_VBN in_IN organic_JJ acidemias_NNS ._.
        Quantitative_NNP analysis_NN of_IN urine_NN organic_JJ acids_NNS by_IN gas_NN
        chromatography_NN /_NN mass_NN spectrometry_NN exhibited_VBN elevated_VBD levels_NNS
        of_IN 3_CD -_: methylglutaconic_JJ (_( 3_CD -_: MGC_NNP )_) acid_NN of_IN 121_CD mmol_NN /_NN mol_NN of_IN
        creatinine_NN (_( normal_JJ range_NN :_: 0_CD -_: 8_CD )_) and_CC 3_CD -_: methylglutaric_JJ (_( 3_CD -_: MGR_NNP )_)
        acid_NN of_IN 33_CD mmol_NN /_NN mol_NN of_IN creatinine_NN (_( normal_JJ range_NN :_: 0_CD -_: 2_LS )_) with_IN a_DT
        normal_JJ level_NN of_IN 3_CD -_: hydroxyisovaleric_JJ acid_NN of_IN 40_CD mmol_NN /_NN mol_NN of_IN
        creatinine_NN (_( normal_JJ range_NN :_: 0_CD -_: 39_CD )_) making_VBG the_DT diagnosis_NN of_IN type_NN
        I_PRP 3_CD -_: MGC_NNP aciduria_NN less_RBR likely_JJ ._. Her_PRP$ urine_NN orotic_JJ acid_NN was_VBD
        mildly_RB elevated_VBD at_IN 81_CD nmoles_NNS orotic_JJ acid_NN /_NN mg_NN creatinine_NN
        (_( normal_JJ range_NN :_: <_NN 60_CD nmoles_NNS orotic_JJ acid_NN /_NN mg_NN creatinine_NN )_) ._.
        At_IN 4_CD days_NNS of_IN age_NN ,_, she_PRP developed_VBD premature_JJ ventricular_NN
        contractions_NNS that_WDT were_VBD immediately_RB followed_VBN by_IN sustained_VBN
        ventricular_NN tachycardia_NN that_IN eventually_RB responded_VBD to_TO
        treatment_NN with_IN β-blockers_JJ ._. Initial_JJ work-up_JJ did_VBD not_RB reveal_VB
        any_DT evidence_NN of_IN a_DT cardiomyopathy_NN ._. A_DT skin_NN biopsy_NN was_VBD
        performed_VBN to_TO rule_VB out_IN carnitine-acylcarnitine_JJ translocase_NN
        deficiency_NN and_CC other_JJ fatty_NN acid_NN oxidation_NN disorders_NNS ._. At_IN 10_CD
        days_NNS of_IN age_NN ,_, the_DT proband_NN was_VBD noted_VBN to_TO have_VB a_DT heart_NN murmur_NN
        and_CC an_DT echocardiogram_NN revealed_VBD at_IN that_DT time_NN ,_, hypertrophic_JJ
        cardiomyopathy_NN with_IN moderate_JJ left_JJ ventricular_NN hypertrophy_NN
        and_CC a_DT left_VBN ventricular_NN shortening_VBG fraction_NN of_IN 30_CD %_NN ._. Her_PRP$
        special_JJ diet_NN was_VBD discontinued_VBN prior_RB to_TO discharge_VB since_IN the_DT
        results_NNS of_IN plasma_NN amino_JJ acids_NNS ,_, urine_NN organic_JJ acids_NNS ,_, and_CC
        urine_NN orotic_JJ acid_NN did_VBD not_RB support_VB the_DT possible_JJ diagnoses_NNS of_IN
        a_DT primary_JJ urea_NN cycle_NN disorder_NN or_CC organic_JJ acidemia_NN as_IN the_DT
        etiology_NN of_IN her_PRP$ hyperammonemia_NN ._. Carnitine-acylcarnitine_NNP
        translocase_NN deficiency_NN or_CC other_JJ type_NN of_IN fatty_NN acid_NN
        oxidation_NN disorder_NN was_VBD suspected_VBN because_IN of_IN her_PRP$ initial_JJ
        presentation_NN ._. Once_RB on_IN full_JJ feeds_VBZ ,_, a_DT trial_NN off_IN sodium_NN
        benzoate_NN ,_, sodium_NN phenylacetate_NN ,_, and_CC arginine_NN resulted_VBD in_IN
        maintenance_NN of_IN her_PRP$ ammonium_NN levels_NNS below_IN 100_CD μmol_NN /_NN L_NNP ._. The_DT
        patient_NN was_VBD discharged_VBN at_IN sixteen_NN days_NNS of_IN age_NN on_IN full_JJ
        breast_NN milk_NN feeds_VBZ ,_, and_CC a_DT β-blocker_JJ ._.
        Fibroblasts_NNP were_VBD incubated_JJ with_IN palmitate_NN labeled_VBN with_IN
        deuterium_NN and_CC L-_NNP carnitine_NN and_CC fatty_NN acid_NN oxidation_NN studies_NNS
        with_IN an_DT 
        in_IN vitro_NN probe_NN were_VBD conducted_VBN ._. Normal_NNP
        levels_NNS of_IN labeled_VBN intermediates_NNS were_VBD observed_VBN from_IN C_NNP 16_CD to_TO
        C_NNP 4_CD without_IN evidence_NN for_IN translocase_NN deficiency_NN or_CC any_DT other_JJ
        type_NN of_IN fatty_NN acid_NN oxidation_NN disorder_NN ._. At_IN two_CD months_NNS of_IN
        age_NN ,_, she_PRP was_VBD mildly_RB hypotonic_JJ on_IN a_DT follow_VB up_RB evaluation_NN and_CC
        the_DT diagnosis_NN of_IN a_DT possible_JJ mitochondrial_NN cytopathy_NN was_VBD
        suspected_VBN ._. Because_IN of_IN a_DT suspicion_NN of_IN a_DT possible_JJ
        mitochondrial_NN disorder_NN ,_, the_DT activities_NNS of_IN pyruvate_NN
        dehydrogenase_NN ,_, pyruvate_NN carboxylase_NN ,_, and_CC mitochondrial_NN
        respiratory_JJ chain_NN enzyme_NN activities_NNS (_( complexes_NNS II-IV_NNP )_) were_VBD
        tested_VBN in_IN fibroblasts_NNS with_IN normal_JJ results_NNS ._. Ophthalmologic_NNP
        and_CC audiologic_JJ evaluations_NNS were_VBD normal_JJ ._. Her_PRP$ urinary_JJ organic_JJ
        acid_NN profile_NN remained_VBD unchanged_JJ in_IN the_DT fasting_VBG and_CC
        postprandial_NN states_NNS ._. Over_IN a_DT period_NN of_IN four_CD years_NNS ,_, the_DT
        patient_NN was_VBD admitted_VBN several_JJ times_NNS for_IN recurrent_JJ Reye-like_NNP
        syndrome_NN episodes_NNS triggered_VBN by_IN viral_JJ illnesses_NNS and_CC
        decreased_VBD oral_JJ intake_NN ._. Though_IN one_CD of_IN these_DT episodes_NNS was_VBD
        associated_VBN with_IN cardiac_JJ arrest_NN at_IN two_CD years_NNS of_IN age_NN ,_, she_PRP
        always_RB responded_VBD well_RB to_TO treatment_NN without_IN apparent_JJ
        neurological_JJ sequelae_NN ._. At_IN 11_CD months_NNS ,_, there_EX was_VBD a_DT concern_NN
        about_IN possible_JJ failure_NN to_TO thrive_VB ,_, nevertheless_RB ,_, her_PRP$ current_JJ
        growth_NN and_CC development_NN at_IN seven_CD years_NNS of_IN age_NN have_VBP been_VBN
        adequate_JJ ._. The_DT proband_NN has_VBZ developed_VBN a_DT clinical_JJ course_NN
        characterized_VBN by_IN increasing_VBG tolerance_NN to_TO fasting_VBG and_CC
        illness_NN without_IN further_JJ episodes_NNS of_IN metabolic_JJ
        decompensation_NN ._. At_IN seven_CD years_NNS of_IN age_NN ,_, she_PRP has_VBZ exhibited_VBN
        fatigue_NN ,_, exercise_NN intolerance_NN and_CC palpitations_NNS as_IN the_DT main_JJ
        features_NNS of_IN abnormal_JJ mitochondrial_NN energy_NN metabolism_NN ._. No_DT
        episodes_NNS of_IN sustained_VBN ventricular_NN tachycardia_NN have_VBP been_VBN
        documented_VBN recently_RB ._. Her_PRP$ cardiomyopathy_NN has_VBZ improved_VBN and_CC
        the_DT results_NNS of_IN her_PRP$ last_JJ echocardiogram_NN showed_VBD mild_JJ left_JJ
        ventricular_NN hypertrophy_NN and_CC a_DT left_VBN ventricular_NN shortening_VBG
        fraction_NN of_IN 50_CD %_NN ._.
      
      
        Methods_NNP
        
          Muscle_NNP biopsy_NN
          A_DT muscle_NN biopsy_NN was_VBD performed_VBN at_IN 30_CD months_NNS of_IN age_NN ,_,
          during_IN a_DT hospitalization_NN for_IN a_DT Reye-like_NNP syndrome_NN
          episode_NN ,_, to_TO further_VB pursue_VB the_DT work-up_JJ of_IN a_DT mitochondrial_NN
          disorder_NN ._. Cryostat_NNP sections_NNS of_IN flash_VBP frozen_VBN muscle_NN were_VBD
          stained_JJ with_IN hematoxylin_NN and_CC eosin_NN ,_, the_DT modified_VBN Gomori_NNP
          trichrome_NN stain_VB ,_, and_CC for_IN succinate_NN dehydrogenase_NN ,_,
          cytochrome_NN c_SYM oxidase_NN activity_NN ,_, reduced_VBN nicotinamide_NN
          adenine_NN dinucleotide_NN (_( NADH_NNP )_) dehydrogenase_NN ,_, and_CC adenosine_NN
          triphosphatase_NN (_( ATPase_NNP )_) activities_NNS at_IN pH_NN 4_CD ._. 3_CD and_CC 4_CD ._. 6_CD ._.
          Muscle_NNP was_VBD also_RB fixed_VBN in_IN glutaraldehyde_NN for_IN electron_NN
          microscopy_NN ._.
        
        
          Respiratory_JJ chain_NN enzyme_NN analysis_NN
          Respiratory_JJ chain_NN enzymes_NNS were_VBD measured_VBN in_IN 10_CD %_NN
          homogenates_NNS using_VBG previously_RB described_VBD methods_NNS as_IN
          follows_VBZ :_: NADH_NNP dehydrogenase_NN [_NN 5_CD ]_NN ,_, NADH_NNP cytochrome_NN c_SYM
          reductase_NN [_NN 5_CD ]_NN ,_, succinate_NN dehydrogenase_NN [_NN 6_CD ]_NN ,_,
          succinate_NN cytochrome_NN c_SYM reductase_NN [_NN 6_CD ]_NN ,_, cytochrome_NN c_SYM
          oxidase_NN [_NN 7_CD ]_NN ,_, and_CC citrate_NN synthase_NN [_NN 8_CD ]_NN ._. Enzyme_NNP
          activities_NNS were_VBD expressed_VBN as_IN μmol_NN /_NN min_NN /_NN g_SYM of_IN wet_JJ weight_NN
          tissue_NN ._.
        
        
          MtDNA_NNP mutation_NN analysis_NN
          MtDNA_NNP from_IN blood_NN and_CC skeletal_NN muscle_NN was_VBD extracted_VBN and_CC
          analyzed_VBN for_IN mtDNA_NN point_NN mutations_NNS ,_, deletions_NNS or_CC
          duplications_NNS by_IN multiplex_NN polymerase_NN chain_NN
          reaction-allele_JJ specific_JJ oligonucleotide_NN (_( PCR_NNP /_NN ASO_NNP )_) dot_VBP
          blot_NN hybridization_NN and_CC Southern_NNP blot_NN analysis_NN ._.
          Quantitative_NNP evaluation_NN of_IN mtDNA_NN content_NN was_VBD performed_VBN in_IN
          skeletal_NN muscle_NN by_IN Southern_NNP blot_NN and_CC Real_NNP Time_NNP
          quantitative_JJ PCR_NNP analyses_NNS [_NN 9_CD ]_NN ._. To_TO look_VB for_IN unknown_JJ
          mtDNA_NN mutations_NNS ,_, the_DT entire_JJ mitochondrial_NN genome_NN was_VBD
          screened_VBD by_IN temporal_JJ temperature_NN gel_NN electrophoresis_NNS
          (_( TTGE_NNP )_) on_IN mother_NN /_NN child_NN pair_NN ,_, followed_VBN by_IN sequencing_VBG of_IN
          the_DT DNA_NNP fragments_NNS that_WDT exhibited_VBN different_JJ banding_VBG
          patterns_NNS between_IN mother_NN and_CC child_NN ._.
        
      
      
        Results_NNS
        
          Muscle_NNP biopsy_NN
          Gomori_NNP trichrome_NN stain_VB revealed_VBD ragged_JJ red_JJ fibers_NNS
          (_( Figure_NN 1_LS )_) ._. Electron_NNP microscopy_NN showed_VBD concentric_JJ
          arrangements_NNS of_IN cristae_NN with_IN rare_JJ dense_JJ bodies_NNS ,_, excess_JJ
          glycogen_NN and_CC fat_JJ deposition_NN ,_, and_CC focal_JJ rare_JJ Z-_NNP disc_NN
          streaming_VBG (_( Figure_NN 2_LS )_) ._.
        
        
          Enzyme_NNP studies_NNS
          The_DT activity_NN of_IN the_DT mitochondrial_NN respiratory_JJ chain_NN
          enzymes_NNS ,_, although_IN mostly_RB below_IN the_DT normal_JJ mean_NN ,_, was_VBD
          within_IN the_DT normal_JJ range_NN in_IN skeletal_NN muscle_NN with_IN moderate_JJ
          increase_NN (_( 52_CD %_NN )_) in_IN the_DT activity_NN of_IN citrate_NN synthase_NN
          suggesting_VBG mitochondrial_NN proliferation_NN (_( Table_NNP 1_LS )_) ._.
        
        
          MtDNA_NNP mutation_NN analysis_NN by_IN PCR_NNP /_NN ASO_NNP dot_VBP blot_NN
          hybridization_NN and_CC Southern_NNP blot_NN
          MtDNA_NNP common_JJ point_NN mutations_NNS (_( MELAS_NNP A_DT 3243_CD G_NNP and_CC T_NN 3271_CD C_NNP ,_,
          MERRF_NNP A_DT 8344_CD G_NNP and_CC T_NN 8356_CD C_NNP ,_, NARP_NNP T_NN 8993_CD G_NNP and_CC T_NN 8993_CD C_NNP ,_,
          cardiomyopathy_NN G_NNP 8363_CD A_DT ,_, and_CC LHON_NNP G_NNP 11778_CD A_DT ,_, G_NNP 3460_CD A_DT ,_, T_NN 14484_CD C_NNP ,_,
          and_CC G_NNP 14459_CD A_DT )_) ,_, deletions_NNS ,_, or_CC duplications_NNS ,_, were_VBD not_RB
          detected_VBN in_IN blood_NN or_CC skeletal_NN muscle_NN ._. A_DT cardiomyopathy_NN
          screen_NN was_VBD negative_JJ for_IN the_DT 6_CD point_NN mutations_NNS in_IN mtDNA_NN
          reported_VBD in_IN patients_NNS with_IN cardiomyopathy_NN :_: A_DT 3243_CD G_NNP ,_, C_NNP 3303_CD T_NN ,_,
          A_DT 4269_CD G_NNP ,_, A_DT 4300_CD G_NNP ,_, G_NNP 8363_CD A_DT and_CC T_NN 9997_CD C_NNP ._.
        
        
          Quantitative_NNP mtDNA_NN analysis_NN
          Quantitative_NNP evaluation_NN of_IN mtDNA_NN content_NN in_IN patient_NN 's_POS
          muscle_NN specimen_NN revealed_VBD no_DT evidence_NN of_IN mtDNA_NN
          depletion_NN ._.
        
        
          TTGE_NNP and_CC MtDNA_NNP sequencing_VBG
          A_DT homoplasmic_JJ T_NN 3197_CD C_NNP nucleotide_NN substitution_NN was_VBD
          detected_VBN in_IN this_DT patient_NN 's_POS blood_NN and_CC muscle_NN and_CC it_PRP was_VBD
          also_RB detected_VBN on_IN the_DT proband_NN 's_POS mother_NN and_CC on_IN two_CD half_NN
          siblings_NNS ._. Both_DT mother_NN and_CC child_NN were_VBD found_VBN to_TO have_VB two_CD
          common_JJ polymorphisms_NNS in_IN homoplasmic_JJ state_NN ,_, G_NNP 185_CD A_DT and_CC
          A_DT 73_CD G_NNP ._. An_DT obvious_JJ difference_NN was_VBD found_VBN in_IN the_DT D-_NNP loop_NN
          region_NN where_WRB A_DT 189_CD G_NNP was_VBD present_JJ in_IN the_DT proband_NN in_IN a_DT near_IN
          homoplasmic_JJ state_NN and_CC homoplasmic_JJ wild_JJ type_NN A_DT 189_CD was_VBD
          present_JJ in_IN the_DT proband_NN 's_POS mother_NN ._. A_DT novel_NN germline_NN
          variation_NN ,_, 568_CD -_: 573_CD insCCCCC_NN ,_, was_VBD present_JJ in_IN both_DT mother_NN
          and_CC the_DT proband_NN ._. Four_CD mtDNA_NN regions_NNS that_WDT did_VBD not_RB
          exhibited_VBN any_DT difference_NN between_IN mother_NN and_CC proband_NN 's_POS
          mtDNA_NN on_IN TTGE_NNP analysis_NN (_( nucleotide_NN position_NN 3085_CD to_TO 3758_CD ,_,
          4013_CD to_TO 4508_CD ,_, 8295_CD to_TO 8600_CD ,_, and_CC 9827_CD to_TO 10286_CD )_) were_VBD
          sequenced_JJ ._. The_DT results_NNS confirmed_VBD the_DT presence_NN of_IN T_NN 3197_CD C_NNP
          polymorphism_NN in_IN both_DT mother_NN and_CC the_DT proband_NN ._. No_DT other_JJ
          mutations_NNS in_IN these_DT regions_NNS ,_, including_VBG the_DT 6_CD point_NN
          mutations_NNS reported_VBD in_IN patients_NNS with_IN cardiomyopathy_NN as_IN
          stated_VBN above_IN ,_, were_VBD detected_VBN ._.
        
      
      
        Discussion_NNP
        
          Reye-like_NNP syndrome_NN episodes_NNS
          Reye_NNP syndrome_NN ,_, a_DT disorder_NN of_IN unknown_JJ cause_NN ,_, is_VBZ
          characterized_VBN by_IN acute_JJ encephalopathy_NN and_CC fatty_NN
          degeneration_NN of_IN the_DT liver_NN and_CC it_PRP is_VBZ usually_RB characterized_VBN
          by_IN a_DT history_NN of_IN preceding_VBG viral_JJ illness_NN or_CC the_DT use_NN of_IN
          aspirin_NN during_IN viral_JJ infections_NNS [_NN 10_CD ]_NN ._. Many_JJ children_NNS
          with_IN metabolic_JJ disorders_NNS present_JJ with_IN Reye-like_NNP syndrome_NN
          episodes_NNS ,_, usually_RB at_IN a_DT young_JJ age_NN and_CC /_NN or_CC with_IN a_DT positive_JJ
          past_NN or_CC family_NN history_NN suspicious_JJ for_IN an_DT inborn_NN error_NN of_IN
          metabolism_NN [_NN 11_CD ]_NN ._. It_PRP has_VBZ been_VBN reported_VBN as_IN a_DT presenting_VBG
          sign_NN of_IN type_NN I_PRP 3_CD -_: MGC_NNP aciduria_NN and_CC in_IN a_DT few_JJ cases_NNS of_IN
          mitochondrial_NN cytopathies_NNS in_IN older_JJR children_NNS [_NN 12_CD 13_CD ]_NN ._.
          However_RB in_IN the_DT neonatal_NN period_NN ,_, a_DT Reye-like_NNP episode_NN is_VBZ
          not_RB a_DT typical_JJ presenting_VBG feature_NN of_IN a_DT mitochondrial_NN
          cytopathy_NN ._.
        
        
          Cardiac_NNP involvement_NN in_IN mitochondrial_NN
          diseases_NNS
          Inborn_NNP errors_NNS of_IN mitochondrial_NN fatty_NN acid_NN oxidation_NN
          should_MD be_VB considered_VBN in_IN infants_NNS with_IN conduction_NN defects_NNS
          or_CC ventricular_NN tachycardia_NN ._. In_IN 24_CD children_NNS with_IN inherited_VBN
          disorders_NNS of_IN fatty_NN acid_NN oxidation_NN ,_, conduction_NN defects_NNS or_CC
          arrhythmias_NNS were_VBD the_DT predominant_NN presenting_VBG feature_NN [_NN 14_CD
          ]_NN ._. Arrhythmias_NNP in_IN association_NN with_IN hepatomuscular_NN
          symptoms_NNS and_CC hyperammonemia_NN have_VBP also_RB been_VBN demonstrated_VBN
          in_IN cases_NNS of_IN carnitine-acylcarnitine_JJ translocase_NN
          deficiency_NN whose_WP$ presenting_VBG features_NNS also_RB include_VBP
          neonatal_NN distress_NN ,_, convulsions_NNS ,_, hypoglycemia_NN ,_,
          hypoketonemia_NN ,_, intermittent_JJ dicarboxylic_JJ aciduria_NN ,_,
          hypothermia_NN ,_, apnea_NN ,_, neurological_JJ deterioration_NN ,_, and_CC
          hypocarnitinemia_NN with_IN grossly_RB elevated_VBD acylcarnitines_NNS [_NN
          15_CD ]_NN ._. The_DT accumulation_NN of_IN arrhythmogenic_JJ metabolites_NNS of_IN
          fatty_NN acids_NNS ,_, such_JJ as_IN long_JJ chain_NN acylcarnitines_NNS ,_, may_MD be_VB
          responsible_JJ for_IN the_DT observed_VBN lethal_JJ cardiac_JJ defects_NNS ._.
          Cardiac_NNP conduction_NN disturbance_NN has_VBZ also_RB been_VBN recognized_VBN
          in_IN the_DT mitochondrial_NN cytopathy_NN ,_, Kearns-_NNP Sayre_NNP syndrome_NN
          (_( Mendelian_NNP inheritance_NN in_IN Man_NN database_NN *_NN 530000_CD )_) ,_,
          characterized_VBN as_IN progressive_JJ external_JJ ophthalmoplegia_NN and_CC
          retinopathy_NN [_NN 16_CD ]_NN ._. Clinical_NNP manifestations_NNS of_IN cardiac_JJ
          disease_NN occur_VB in_IN 57_CD %_NN of_IN patients_NNS with_IN Kearns-_NNP Sayre_NNP
          syndrome_NN [_NN 17_CD ]_NN ._. The_DT complete_JJ AV_NNP block_VB in_IN Kearns-_NNP Sayre_NNP
          syndrome_NN may_MD also_RB be_VB associated_VBN less_RBR commonly_RB with_IN
          ventricular_NN tachycardia_NN ,_, torsade_NN de_IN pointes_NNS and_CC
          ventricular_NN fibrillation_NN as_IN the_DT ultimate_JJ and_CC often_RB fatal_JJ
          stage_NN of_IN the_DT condition_NN [_NN 18_CD ]_NN ._. However_RB ,_, to_TO our_PRP$
          knowledge_NN ,_, ventricular_NN tachycardia_NN as_IN a_DT presenting_VBG
          feature_NN has_VBZ not_RB been_VBN described_VBN in_IN the_DT context_NN of_IN
          mitochondrial_NN cytopathies_NNS in_IN the_DT neonatal_NN period_NN ._.
        
        
          Causes_NNP of_IN 3_CD -_: MGC_NNP aciduria_NN in_IN children_NNS
          3_LS -_: MGC_NNP aciduria_NN is_VBZ a_DT rare_JJ hereditary_JJ organic_JJ aciduria_NN
          characterized_VBN by_IN increased_VBN urinary_JJ excretion_NN of_IN 3_CD -_: MGC_NNP and_CC
          3_CD -_: MGR_NNP acids_NNS ._. At_IN least_JJS 4_CD distinct_JJ clinical_JJ forms_NNS
          associated_VBN with_IN 3_CD -_: MGC_NNP aciduria_NN have_VBP been_VBN described_VBN [_NN 19_CD ]_NN
          ._. Type_NNP I_PRP 3_CD -_: MGC_NNP aciduria_NN (_( Mendelian_NNP Inheritance_NNP in_IN Man_NN
          database_NN *_NN 250950_CD )_) due_JJ to_TO 3_CD -_: MGC_NNP CoA_NNP hydratase_NN (_( EC_NNP
          4_CD ._. 2_CD ._. 1_LS ._. 18_CD )_) deficiency_NN has_VBZ a_DT relatively_RB benign_JJ clinical_JJ
          course_NN including_VBG speech_NN delay_NN and_CC macrochephaly_RB ;_: type_NN II_NNP
          3_CD -_: MGC_NNP aciduria_NN (_( Barth_NNP syndrome_NN )_) (_( Mendelian_NNP Inheritance_NNP in_IN
          Man_NN database_NN *_NN 302060_CD )_) has_VBZ a_DT clinical_JJ picture_NN that_WDT
          includes_VBZ cardiomyopathy_NN ,_, recurrent_JJ infections_NNS ,_,
          neutropenia_NN ,_, short_JJ stature_NN and_CC normal_JJ cognitive_JJ function_NN
          and_CC is_VBZ caused_VBN by_IN mutations_NNS in_IN the_DT tafazzin_NN gene_NN (_( G_NNP 4_CD ._. 5_LS )_) [_NN
          20_CD ]_NN ;_: type_NN III_NNP 3_CD -_: MGC_NNP aciduria_NN (_( Costeff_NNP optic_JJ atrophy_NN
          syndrome_NN )_) (_( Mendelian_NNP Inheritance_NNP in_IN Man_NN database_NN *_NN 258501_CD )_)
          was_VBD described_VBN in_IN patients_NNS of_IN Iraqi-_NNP Jewish_JJ origin_NN with_IN
          bilateral_JJ optic_JJ atrophy_NN accompanied_VBN in_IN some_DT by_IN movement_NN
          disorders_NNS and_CC caused_VBN by_IN mutations_NNS in_IN the_DT OPA_NNP 3_CD gene_NN [_NN 21_CD
          22_CD ]_NN ;_: and_CC type_NN IV_NNP 3_CD -_: MGC_NNP aciduria_NN (_( Mendelian_NNP Inheritance_NNP
          in_IN Man_NN database_NN *_NN 250951_CD )_) presents_VBZ with_IN moderate_JJ to_TO severe_JJ
          neurological_JJ disease_NN ,_, cardiac_JJ ,_, ophthalmic_JJ ,_, hepatic_JJ ,_, and_CC
          renal_JJ symptoms_NNS and_CC it_PRP has_VBZ been_VBN associated_VBN with_IN
          mitochondrial_NN disorders_NNS (_( Pearson_NNP syndrome_NN ,_, mitochondrial_NN
          DNA_NNP depletion_NN )_) or_CC multiple_JJ respiratory_JJ chain_NN defects_NNS [_NN 23_CD
          24_CD 25_CD 26_CD ]_NN ._. This_DT group_NN does_VBZ not_RB have_VB a_DT defined_VBN primary_JJ
          biochemical_JJ or_CC molecular_JJ defect_NN ._. Our_PRP$ patient_NN would_MD fit_VB in_IN
          this_DT latter_NN clinically_RB heterogeneous_JJ group_NN although_IN the_DT
          degree_NN of_IN elevation_NN of_IN 3_CD -_: MGC_NNP seen_VBN in_IN other_JJ cases_NNS could_MD be_VB
          as_RB high_JJ as_IN 600_CD mmol_NN /_NN mol_NN of_IN creatinine_NN ._. Barth_NNP syndrome_NN ,_, a_DT
          cause_NN of_IN 3_CD -_: MGC_NNP aciduria_NN and_CC cardiomyopathy_NN ,_, would_MD be_VB an_DT
          unlikely_JJ diagnosis_NN in_IN our_PRP$ patient_NN primarily_RB due_JJ to_TO
          absence_NN of_IN symptoms_NNS in_IN female_JJ carriers_NNS secondary_JJ to_TO
          presumed_VBN skewing_VBG of_IN X-_NNP inactivation_NN and_CC lack_NN of_IN growth_NN
          retardation_NN and_CC neutropenia_NN ._. We_PRP suspect_VBP that_IN her_PRP$ organic_JJ
          aciduria_NN is_VBZ associated_VBN with_IN mitochondrial_NN dysfunction_NN ._. It_PRP
          has_VBZ been_VBN speculated_VBN that_IN an_DT abnormality_NN of_IN translocation_NN
          of_IN 3_CD -_: MGC_NNP acid_NN across_IN the_DT mitochondrial_NN membrane_NN may_MD be_VB
          the_DT source_NN of_IN 3_CD -_: MGC_NNP aciduria_NN in_IN these_DT patients_NNS [_NN 23_CD ]_NN ._.
          The_DT link_NN between_IN 3_CD -_: MGC_NNP aciduria_NN and_CC mitochondrial_NN
          dysfunction_NN may_MD involve_VB failure_NN of_IN mitochondrial_NN uptake_NN
          of_IN 3_CD -_: MGC_NNP acid_NN or_CC potentially_RB defective_JJ ubiquinone_NN
          biosynthesis_NNS leading_VBG to_TO increased_VBN levels_NNS of_IN mevalonate_NN in_IN
          the_DT mevalonate_NN shunt_NN pathway_NN with_IN subsequent_JJ increased_VBN
          synthesis_NN of_IN 3_CD -_: MGC_NNP acid_NN [_NN 27_CD ]_NN ._.
        
        
          MtDNA_NNP mutation_NN analysis_NN
          Although_IN there_EX is_VBZ no_DT direct_JJ proof_NN of_IN a_DT respiratory_JJ
          chain_NN (_( RC_NNP )_) defect_NN in_IN our_PRP$ patient_NN ,_, mitochondrial_NN disorders_NNS
          cannot_NN be_VB ruled_VBN out_IN ,_, as_IN normal_JJ RC_NNP activities_NNS have_VBP been_VBN
          occasionally_RB reported_VBN in_IN muscle_NN samples_NNS from_IN clinically_RB
          affected_VBN patients_NNS with_IN proven_VBN mtDNA_NN mutations_NNS or_CC
          mutations_NNS in_IN nuclear_JJ genes_NNS that_WDT impact_NN mitochondrial_NN
          function_NN [_NN 28_CD 29_CD 30_CD ]_NN ._. Respiratory_JJ chain_NN activity_NN
          studies_NNS on_IN endomyocardial_NN biopsy_NN would_MD be_VB helpful_JJ ._. Since_IN
          no_DT primary_JJ deleterious_JJ mtDNA_NN mutation_NN has_VBZ been_VBN found_VBN in_IN
          the_DT proband_NN and_CC she_PRP was_VBD born_VBN to_TO healthy_JJ parents_NNS with_IN
          unremarkable_JJ family_NN history_NN ,_, we_PRP hypothesize_NN that_IN the_DT
          etiology_NN of_IN her_PRP$ mitochondrial_NN dysfunction_NN could_MD reside_VB in_IN
          a_DT still_RB unidentified_JJ nuclear_JJ gene_NN defect_NN ;_: although_IN
          secondary_JJ mitochondrial_NN dysfunction_NN caused_VBN by_IN an_DT unknown_JJ
          inborn_NN error_NN of_IN metabolism_NN cannot_NN be_VB excluded_VBN completely_RB ._.
          At_IN the_DT present_JJ time_NN ,_, the_DT T_NN 3197_CD C_NNP nucleotide_NN substitution_NN
          is_VBZ considered_VBN a_DT polymorphism_NN and_CC it_PRP is_VBZ not_RB thought_VBN to_TO
          have_VB pathogenic_JJ significance_NN by_IN itself_PRP [_NN 31_CD ]_NN ._. Although_IN
          most_JJS pathogenic_JJ mutations_NNS are_VBP heteroplasmic_JJ ,_, many_JJ
          homoplasmic_JJ mutations_NNS have_VBP been_VBN reported_VBN to_TO have_VB
          synergistic_JJ effects_NNS in_IN the_DT presence_NN of_IN other_JJ primary_JJ
          mutations_NNS [_NN 32_CD 33_CD ]_NN ._. The_DT only_JJ difference_NN in_IN mtDNA_NN
          between_IN the_DT affected_VBN child_NN and_CC the_DT asymptomatic_JJ mother_NN is_VBZ
          the_DT A_DT 189_CD G_NNP mutation_NN in_IN the_DT hypervariable_JJ D-_NNP loop_NN region_NN ._.
          The_DT A_DT 189_CD G_NNP has_VBZ been_VBN reported_VBN as_IN a_DT polymorphism_NN in_IN Mitomap_NNP
          database_NN [_NN 34_CD ]_NN ._. Whether_IN this_DT alteration_NN would_MD affect_VB
          mtDNA_NN replication_NN or_CC transcription_NN is_VBZ not_RB known_VBN ._. A_DT
          remarkable_JJ finding_NN was_VBD the_DT novel_NN 568_CD -_: 573_CD insCCCCC_NN ,_,
          present_JJ in_IN both_DT mother_NN and_CC proband_NN ._. This_DT region_NN contains_VBZ
          a_DT stretch_NN of_IN 6_CD cytosines_NNS (_( C_NNP 's_POS )_) in_IN the_DT wild_JJ type_NN ._. The_DT
          insertion_NN of_IN 5_CD C_NNP 's_POS results_NNS in_IN a_DT long_JJ polyC_NN tract_NN ._. The_DT
          polyC_NN tract_NN is_VBZ located_VBN next_JJ to_TO the_DT mitochondrial_NN
          transcription_NN factor_NN 1_CD (_( mtTF_NN 1_LS )_) binding_JJ site_NN and_CC the_DT major_JJ
          H-_NNP strand_NN promoter_NN sequence_NN ._. It_PRP is_VBZ not_RB clear_JJ if_IN the_DT length_NN
          of_IN this_DT poly_RB C_NNP stretch_NN would_MD influence_VB promoter_NN activity_NN
          or_CC mtTF_NN 1_CD binding_JJ ,_, thus_RB ,_, the_DT transcription_NN of_IN
          mitochondrial_NN RNA_NNP ._. Further_RB investigations_NNS are_VBP necessary_JJ
          to_TO define_VB the_DT clinical_JJ significance_NN of_IN the_DT homoplasmic_JJ
          mtDNA_NN alterations_NNS found_VBD in_IN the_DT proband_NN and_CC to_TO know_VB
          whether_IN they_PRP may_MD act_VB as_IN secondary_JJ mutations_NNS ,_,
          synergistically_RB with_IN a_DT primary_JJ defect_NN (_( either_CC nuclear_JJ or_CC
          mitochondrial_NN )_) that_WDT could_MD affect_VB the_DT mitochondrial_NN
          function_NN and_CC result_NN in_IN this_DT clinical_JJ condition_NN ._.
        
        
          Orotic_NNP aciduria_NN and_CC abnormal_JJ acylcarnitine_NN profile_NN
          as_IN potential_JJ markers_NNS of_IN mitochondrial_NN disease_NN
          It_PRP has_VBZ been_VBN reported_VBN before_IN that_IN an_DT increased_VBN
          excretion_NN of_IN orotate_NN in_IN sick_JJ children_NNS may_MD not_RB be_VB uncommon_JJ
          and_CC that_IN a_DT positive_JJ allopurinol_NN load_NN test_NN may_MD indicate_VB
          unrecognized_JJ mitochondrial_NN disease_NN ,_, making_VBG orotic_JJ acid_NN as_IN
          a_DT potential_JJ marker_NN of_IN mitochondrial_NN dysfunction_NN [_NN 35_CD ]_NN ._.
          A_DT potential_JJ link_NN between_IN mitochondrial_NN cytopathies_NNS and_CC
          urea_NN cycle_NN dysfunction_NN has_VBZ also_RB been_VBN suggested_VBN by_IN the_DT
          findings_NNS of_IN hypocitrullinemia_NN in_IN patients_NNS with_IN neurogenic_JJ
          weakness_NN ,_, ataxia_NN and_CC retinitis_NNS pigmentosa_NN (_( NARP_NNP )_) syndrome_NN
          (_( Mendelian_NNP Inheritance_NNP in_IN Man_NN database_NN *_NN 551500_CD )_) caused_VBN by_IN
          a_DT T_NN 8993_CD G_NNP mutation_NN in_IN mtDNA_NN that_WDT triggers_VBZ ATPase_NNP
          deficiency_NN [_NN 36_CD 37_CD ]_NN ._. It_PRP was_VBD hypothesized_VBN that_IN the_DT NARP_NNP
          mutation_NN would_MD cause_VB complex_JJ V_NNP deficiency_NN in_IN the_DT small_JJ
          intestine_NN as_IN well_RB ,_, thus_RB reducing_VBG the_DT availability_NN of_IN
          mitochondrial_NN ATP_NNP required_VBD for_IN citrulline_NN synthesis_NN ._. The_DT
          presence_NN of_IN mild_JJ increase_NN in_IN the_DT urinary_JJ excretion_NN of_IN
          orotic_JJ acid_NN in_IN this_DT patient_NN could_MD also_RB suggest_VB
          mitochondrial_NN dysfunction_NN ,_, convalidating_VBG this_DT
          hypothesis_NNS ._.
          It_PRP has_VBZ been_VBN noticed_VBN that_IN if_IN a_DT patient_NN is_VBZ suspected_VBN of_IN
          having_VBG a_DT mitochondrial_NN disease_NN ,_, abnormal_JJ carnitine_NN esters_NNS
          may_MD help_VB with_IN the_DT diagnosis_NN ,_, [_NN 38_CD ]_NN and_CC abnormal_JJ
          acylcarnitine_NN profiles_NNS do_VBP not_RB exclusively_RB indicate_VB fatty_NN
          acid_NN oxidation_NN disorders_NNS [_NN 39_CD ]_NN ._. Although_IN the_DT abnormal_JJ
          carnitine_NN ester_NN present_JJ in_IN the_DT proband_NN is_VBZ elevated_VBD in_IN
          organic_JJ acidemias_NNS and_CC is_VBZ not_RB usually_RB present_JJ in_IN
          mitochondrial_NN cytopathies_NNS ,_, we_PRP speculate_VBP that_IN due_JJ to_TO
          compromised_VBN ATP_NNP synthesis_NN ,_, secondary_JJ alterations_NNS may_MD be_VB
          generated_VBN in_IN these_DT patients_NNS by_IN changes_NNS in_IN mitochondrial_NN
          protein_NN synthesis_NN ,_, decrease_VB in_IN Krebs_NNP cycle_NN intermediates_NNS
          and_CC increased_VBN free_JJ radical_JJ formation_NN ,_, that_WDT could_MD be_VB
          responsible_JJ for_IN a_DT secondary_JJ impairment_NN of_IN mitochondrial_NN
          biotin_NN dependent_JJ carboxylases_NNS ,_, but_CC further_JJ elucidation_NN is_VBZ
          necessary_JJ before_IN we_PRP could_MD arrive_VB to_TO a_DT conclusion_NN in_IN this_DT
          regard_NN ._.
        
      
      
        Conclusions_NNP
        Although_IN alterations_NNS in_IN mitochondrial_NN morphology_NN do_VBP not_RB
        necessarily_RB reflect_VB well-defined_JJ mitochondrial_NN disorders_NNS
        and_CC we_PRP cannot_NN completely_RB exclude_VB the_DT possibility_NN of_IN an_DT
        unknown_JJ metabolic_JJ disorder_NN with_IN secondary_JJ mitochondrial_NN
        dysfunction_NN ,_, we_PRP speculate_VBP that_IN all_PDT the_DT clinical_JJ ,_,
        biochemical_JJ and_CC histological_JJ features_NNS in_IN the_DT proband_NN can_MD be_VB
        attributed_VBN to_TO disturbed_VBN mitochondrial_NN energy_NN metabolism_NN ._. We_PRP
        suspect_VBP that_IN this_DT proband_NN 's_POS 3_CD -_: MGC_NNP aciduria_NN reflects_VBZ a_DT
        defect_NN in_IN mitochondrial_NN energy_NN metabolism_NN and_CC that_IN her_PRP$ mild_JJ
        orotic_JJ aciduria_NN may_MD be_VB a_DT nonspecific_JJ marker_NN of_IN
        mitochondrial_NN dysfunction_NN ._. Mitochondrial_NNP cytopathies_NNS are_VBP a_DT
        group_NN of_IN disorders_NNS that_WDT are_VBP clinically_RB heterogeneous_JJ with_IN
        variable_JJ forms_NNS of_IN presentation_NN ._. We_PRP conclude_VBP that_DT
        ventricular_NN tachycardia_NN in_IN association_NN with_IN a_DT Reye-like_NNP
        syndrome_NN episode_NN in_IN the_DT neonatal_NN period_NN may_MD suggest_VB
        mitochondrial_NN dysfunction_NN ,_, and_CC that_IN the_DT investigation_NN of_IN a_DT
        mitochondrial_NN cytopathy_NN may_MD be_VB warranted_VBN in_IN this_DT clinical_JJ
        scenario_NN ._. Our_PRP$ patient_NN 's_POS neonatal_NN presentation_NN and_CC
        relatively_RB mild_JJ clinical_JJ course_NN broadens_VBZ the_DT heterogeneous_JJ
        spectrum_NN of_IN clinical_JJ phenotypes_NNS associated_VBN with_IN altered_VBN
        mitochondrial_NN energy_NN metabolism_NN ._.
      
      
        List_NN of_IN abbreviations_NNS
        Mitochondrial_NNP DNA_NNP (_( MtDNA_NNP )_)
        3_LS -_: methylglutaconic_JJ (_( 3_CD -_: MGC_NNP )_)
        3_LS -_: methlyglutaric_JJ (_( 3_CD -_: MGA_NNP )_)
        Polymerase_NNP chain_NN reaction-allele_JJ specific_JJ
        oligonucleotide_NN (_( PCR_NNP /_NN ASO_NNP )_)
        Temporal_NNP temperature_NN gel_NN electrophoresis_NNS (_( TTGE_NNP )_)
        Cytosine_NNP (_( C_NNP )_)
        Mitochondrial_NNP transcription_NN factor_NN 1_CD (_( MtTF_NNP 1_LS )_)
        Neurogenic_NNP weakness_NN ,_, ataxia_NN ,_, and_CC retinitis_NNS pigmentosa_NN
        (_( NARP_NNP )_)
        Respiratory_JJ chain_NN (_( RC_NNP )_)
        NADH_NNP :_: reduced_VBN nicotinamide_NN adenine_NN dinucleotide_NN
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        FS_NNP -_: provided_VBN long_JJ term_NN subspecialty_NN care_NN of_IN the_DT
        patient_NN ,_, evaluated_VBD the_DT patient_NN and_CC composed_VBN the_DT
        manuscript_NN ._.
        AS_NNP -_: provided_VBN care_NN during_IN first_JJ admission_NN and_CC initial_JJ
        follow_VB up_RB ,_, and_CC made_VBD the_DT primary_JJ diagnosis_NN ._.
        JT_NNP -_: evaluated_VBN /_NN managed_VBD the_DT patient_NN 's_POS cardiac_JJ arrhythmia_NN
        and_CC cardiomyopathy_NN ._.
        DA_NNP -_: performed_VBN and_CC interpreted_VBD the_DT specialized_JJ
        histochemical_JJ and_CC electron_NN microscopy_NN studies_NNS on_IN the_DT muscle_NN
        biopsy_NN specimen_NN ._.
        LS_NNP -_: performed_VBN and_CC interpreted_VBD the_DT quantitative_JJ urine_NN
        organic_JJ acid_NN analysis_NN ._.
        L-JW_NNP -_: performed_VBN and_CC interpreted_VBD the_DT specialized_JJ
        mitochondrial_NN DNA_NNP molecular_JJ studies_NNS ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
